Gastrointestinal Tract Infections, Respiratory Tract Infections
Conditions
Brief summary
Hypothesis: Use of Bifidobacterium animalis subsp. lactis can effectively prevent common infections (gastrointestinal and respiratory) in healthy children who attend day care centre This study is a prospective, randomized, double blind, placebo- controlled parallel study in healthy children attending day care centers. The study will investigate the effect of supplementation with the probiotic strain Bifidobacterium animalis subsp. lactis on the incidence and duration of gastrointestinal and respiratory infections and absence from day care due to infections. The test product is a sachet containing 1 gram of powder. The test product will contain minimum 1 billion CFU (colony forming units) of probiotic per serving. The placebo product is an identical product except for the absence of probiotics. The study includes 3 months (90 days) of intervention period. The study product will be consumed daily in the evening together with a meal. The consumption of the study products will be taken under the surveillance of the parents. During the entire intervention period the subjects are not allowed to consume any probiotic products other than the study products supplied to them by the study personnel. Data on infections will be recorded in a diary, filled in and administered by the parents and diary recorded by referring physician (on-call log). All infections are to be diagnosed by the local physician. The incidence of infections will be analyzed based on the information recorded in the diaries (parent's & physician's).
Interventions
DIETARY_SUPPLEMENTBifidobacterium animalis subsp. lactis
Sponsors
Children's Hospital Zagreb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
1 Years to 7 Years
Inclusion criteria
* Healthy children attending day care at kindergartens located in the Zagreb's city centre * Age from 1 year to 7 years * Attendance at daycare centers: \> 3 days per week * Signed informed consent by the parents
Exclusion criteria
* Immunodeficiency * Receiving probiotic and /or prebiotic products prior to enrolment (2 weeks prior to study start) * Neoplasms * Severe chronic disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Common infections | — | Number of children with gastrointestinal tract infections defined as diarrhoea (3 or more loose or watery stools in 24 hours or increase of number of stools for more than 50% in 24 hours) or vomiting (defined by physician and not a result of other symptoms including cough or diseases including gastroesophageal reflux disease or neurological conditions) or both. And number of children with respiratory tract infections defined as: pharyngitis, otitis, common cold, pneumonia, bronchitis and bronciolitis (all infections diagnosed by physician) Number of children with adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of symptoms | — | Duration of symptoms in days |
Other
| Measure | Time frame | Description |
|---|---|---|
| Infections with determined infective cause | — | Number of gastrointestinal and erspiratory tract infections with proven infective cause (if determined) |
Countries
Croatia
Outcome results
None listed